Welcome to our dedicated page for Thermogenesis Holdings news (Ticker: THMO), a resource for investors and traders seeking the latest updates and insights on Thermogenesis Holdings stock.
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) drives innovation in automated cell therapy technologies, specializing in CAR-T manufacturing solutions and clinical biobanking systems. This page aggregates all official announcements, financial disclosures, and strategic developments for investors and industry professionals.
Access real-time updates on the CAR-TXpress platform advancements, facility expansions like the Sacramento CDMO complex with ISO 7 cleanrooms, and partnership announcements. Track quarterly financial results, leadership changes, and regulatory milestones impacting the cell therapy sector.
Key content includes earnings reports, product launch details, manufacturing capacity updates, and collaborations with biotech partners. The curated news feed enables efficient monitoring of THMO's transition from medical device specialist to full-service cell therapy CDMO.
Bookmark this page for streamlined access to verified information about ThermoGenesis' automated bioprocessing systems and cryopreservation technologies. Check regularly for developments affecting the $4.3B CAR-T market and broader cell therapy landscape.
ThermoGenesis Holdings, Inc. (THMO) announced the completion of the development and FDA submission for its PXP-LAVARE System, an automated cell processing system aimed at improving the manufacturing of cell-based therapies, including CAR-T cells. The system is GMP compliant and features a control module, docking station, and disposable cartridge, all intended for cGMP clinical manufacturing. CEO Chris Xu highlighted the company's commitment to innovation in the rapidly expanding cell and gene therapy market.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announced that CFO Jeff Cauble will present a company overview at the H.C. Wainwright BIOCONNECT 2021 Conference on January 11 at 6:00 am ET. The presentation will be accessible on ThermoGenesis' website and archived for 90 days. The company specializes in automated technologies for CAR-T and cell-based therapies, offering a range of solutions for clinical biobanking and immuno-oncology. For further details, visit their website.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported net revenues of $2.4 million for Q3 2020, a 42% drop from $4.1 million in Q3 2019. This decline was attributed to reduced AXP® disposable and CAR-TXpress™ sales, impacted by the COVID-19 pandemic. Gross profit decreased to $1.5 million, representing 64% of net revenues. The company posted a net loss of $2.5 million, or $(0.37) per share. Adjusted EBITDA showed a loss of $672,000, a significant decline from a gain of $125,000 in the prior year. However, cash reserves improved to $4.4 million.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) is set to release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020. Following the announcement, the company will hold a conference call and webcast at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide a corporate strategic update. The company specializes in automated cell processing tools and services, primarily for the cell and gene therapy sector.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) has announced it will receive U.S. Patent No. 10,823,746 for its innovative lateral flow immunoassay test reader technology, the ThermoGenesis Reader, on November 3. This technology aims to enhance the deployment of COVID-19 vaccines by prioritizing seronegative individuals during limited supply phases. The Reader features advanced laser-scanning capabilities and will begin production in December, anticipating vaccine approvals. FDA-authorized LFIA cartridges will be certified for use with the Reader, promoting efficient monitoring of vaccine responses.
On September 2, 2020, ThermoGenesis Holdings (Nasdaq: THMO) partnered with its joint venture, ImmuneCyte, to launch a comprehensive suite of products aimed at combating the COVID-19 pandemic. This strategy includes both diagnostics and therapeutics, enhancing disease detection and treatment. Key elements involve the development of various RT-PCR and antigen tests, complementing the already authorized SARS-CoV-2 IgM/IgG Antibody Test Kit. The initiative positions ThermoGenesis as a one-stop solution for COVID-19 testing and treatment, as discussed in their presentation at the LD Micro 500 Conference.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a leader in cell processing technologies, announced participation in two upcoming investor conferences in September 2020. CEO Chris Xu will present at the LD Micro 500 on September 2 at 5:00 pm ET, with a live webcast available on their website. CFO Jeff Cauble will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 12:00 pm ET, also accessible via webcast. Archived replays of both presentations will be available for 90 days post-conference.
ThermoGenesis Holdings, Inc. (THMO) reported a Q2 2020 net revenue of $2.2 million, down 48% from $4.3 million in Q2 2019. This decline was due to reduced AXP disposable sales amid the COVID-19 pandemic, affecting the cord blood industry. Gross profit was a loss of $2.6 million compared to a profit of $2.0 million year-over-year. However, CAR-TXpress™ sales increased by $400,000 thanks to distributor Corning. The company expects sales to return to normal post-pandemic and is strategically expanding its product offerings, including COVID-19 solutions.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announced a supply agreement with BioHit Healthcare to market a SARS-CoV-2 IgM/IgG Antibody Test Kit, which has received Emergency Use Authorization (EUA) from the FDA. Marketing of the test kit is set to begin on August 17, 2020. The company has also withdrawn its own EUA submission for a previously announced antibody detection kit. ThermoGenesis is working on a companion reader to enhance serological testing accuracy and tracking, aiming to contribute to pandemic monitoring efforts.
